Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

NCT00585221 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped PI terminated at the recommendation of DSMC \& IRB

Conditions

Gastrointestinal Stromal Tumors
Cancer Brain
Solid Tumors

Interventions

DRUG: Peginterferon-alpha 2b (PegIFNa2b);
DRUG: Imatinib

Sponsor

University of Utah

Collaborators

[object Object]